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patients with chronic hepatitis C
Ribavirin is a nucleoside analogue which interferes with viral
replication. Although its mechanism of action is not entirely
understood, it is phosphorylated upon cell entry, inhibits cellular
monophosphate dehydrogenase, and depletes intracellular gua-
nosine triphosphate as well as cell methylation. It interferes with
viral capping, inhibits viral polymerases, and induces mutagene-
sis. Preclinical studies in mice and rats have repeatedly conﬁrmed
the mutagenic potential of ribavirin reported to induce congeni-
tal malformations of the limbs, the bones, the spine, and the cen-
tral nervous system. Ribavirin treatment led to a dose dependent
decrease in spermatozoa counts and altered morphology in
experimental animals. Although not conﬁrmed in humans, these
early observations lead to very strict recommendations for dou-
ble barrier contraception for a period of at least 6 months after
the end of treatment in patients with chronic hepatitis C (CHC).
However, information on the outcome of babies conceived and
born to CHC parents treated with ribavirin (and interferon), is
scarce. In humans, only 22 pregnancies occurring within three
months of male ribavirin treatment have been reported in 4 stud-
ies (reviewed in [1]). No malformations were reported in 11
healthy born babies. However, one third of the pregnancies ended
with a miscarriage and seven babies were lost to follow-up. Du-
razzo and co-workers [2] reported a potential harmful effect of
HCV infection (as an extra-hepatic manifestation of HCV) and
possibly of ribavirin on spermatogenesis in humans, manifested
by morphological alterations associated with altered sperm
motility. Recently, a ﬁrst case report described a ribavirin associ-
ated fragmentation of sperm DNA as well as morphological and
functional alterations in a patient with CHC which lasted for eight
months after cessation of combined anti-viral therapy [1].
In this issue of the journal, Hofer and co-workers extended the
preliminary observations available by analyzing seminal ﬂuid
obtained from 15 male CHC patients (genotypes 1, 2, 3, and 4),
before and during initial combined treatment with ribavirin
(800–1200 mg/day) and pegylated interferon a2a. For the ﬁrst
time, investigators observed an increased concentration of ribavi-
rin in seminal ﬂuid as compared to serum levels. Altered sperm
morphology, motility, and density was already present before ini-
tiation of anti-viral therapy, conﬁrming the observation of Dur-
azzo et al. that sperm abnormalities may develop as an extra-
hepatic manifestation of CHC. Yet, all the tested parameters
worsened by week 12 of anti-viral therapy. HCV RNA was
detected in only two patients prior to therapy. Indeed, as alsoJournal of Hepatology 20
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study does not enable any assessment as to whether the effects
caused by anti-viral treatment are reversible. However, these
results support the assessment that ribavirin has undesirable
effects on spermatogenesis irrespective of HCV infection. The
effect of interferon a on spermatogenesis is not entirely estab-
lished. However, based on previous observations and the current
report, it appears that ribavirin is mainly responsible for the qual-
itative and quantitative changes in spermatogenesis in addition
to HCV itself. It should be remembered, that in spite of existing
evidence from experimental animals, there have been no reports
on teratogenicity in living human infants whose parents were
treated with ribavirin. It is therefore important to report all preg-
nancies and deliveries of infants born to anti-viral treated CHC
parents to the ribavirin pregnancy registry (www.ribavirinpre-
gnancyregistry.com). The information provided by this registry
will be useful in counseling CHC patients pending anti-viral ther-
apy. Finally, it is not yet known and to what extent, whether the
effects of ribavirin on spermatogenesis are reversible. Further
studies in a larger cohort of patients, extending into the post-
treatment period, are desired.
Anti-viral therapy of children with chronic hepatitis C: what are the
arguments for early treatment?
The relatively high incidence of transfusion transmitted hepatitis
C virus (HCV) infection previously observed in children with
hematologic diseases is declining rapidly due to improved
screening of blood and blood products introduced in the early
1990s. HCV infection in children is now most frequently acquired
through vertical transmission from infected mothers. The rate of
vertical transmission varies between 4% and 6% and may be
higher in children born to mothers co-infected with HCV and
HIV. Chronic HCV infection (CHC) is usually mild and asymptom-
atic in the pediatric population who often has normal alanine
aminotransferase levels. Until recently, many pediatricians were
reluctant to test newborn and young babies at risk for HCV or
offer anti-viral therapy with interferon (or pegylated interferon)
and ribavirin to infected children. There are however a number
of arguments which support a more proactive approach in such
patients. These include among others the shorter duration of
infection, the lower viral load, and the limited ﬁbrosis observed
in children linked to improved efﬁcacy of anti-viral therapy. Fur-
thermore, cumulative experience obtained in a number of stud-
ies, conducted mainly in Europe, suggested a better tolerability
to anti-viral therapy as compared to adult patients with CHC.
Finally, despite the relatively benign course of CHC in children,
some will progress to cirrhosis and even require liver
transplantation.10 vol. 52 j 781–782
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In this issue of the journal, Sokal and co-workers report their
excellent results in anti-HCV treatment with pegylated interferon
a2a and ribavirin on 18 patients with HCV genotypes 2 and 3 and
47 children with genotypes 1, 4, 5, and 6. Sustained viral response
(SVR) was achieved in 89% of the former and 57% of the later
group, respectively. Furthermore, 93% of patients with genotypes
2 and 3 and 81% of patients with the remaining genotypes, who
reached an early virologic response, also achieved SVR. Adverse
events were similar to those reported in adults with a somewhat
higher rate of thyroid dysfunction but without an effect of treat-
ment on growth. The results in two groups of children recruited
in Belgium, Brazil, Latvia, the UK, and Sweden (mean age 11.6–
12.6 years) are indeed superior to those reported in many studies
in adults and support the advocates of early treatment of CHC in
Children. The study has a number of limitations including the
inability for accurate comparison to data obtained in adults due
to the relatively small pediatric population studied. A similar
study in a larger cohort should provide further information782 Journal of Hepatology 201regarding the impact of the metabolic syndrome and fatty liver
in response to treatment, the optimal age for starting anti-viral
therapy, and the rate of SVR in children with various hematologic
diseases. It would also be interesting to know if and what was the
impact of treatment on behavior, cognitive function, and perfor-
mance at school. All in all, this study conﬁrms the outstanding
response to anti-viral therapy in children with CHC, genotypes
2 and 3, and the improved results in children with genotypes 1,
4, 5, and 6 as compared to adults.
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